Benitec Biopharma Inc. (BNTC)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Benitec Biopharma Inc. (BNTC) is down 8.7% since the beginning of the year. At $12 per share, BNTC is trading 26.6% below its 52-week high of $17. Investors who bought $1,000 worth of BNTC shares 5 years ago would now be looking at an investment worth $169.

Benitec Biopharma Inc. (BNTC) has returned -8.69% so far this year and -15.81% over the past 12 months. Over the last ten years, BNTC has returned -28.11% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.

Based on dividend-adjusted daily data since Aug 18, 2015, BNTC's average daily return is +0.07%, while the average monthly return is -1.33%.

Historically, 44% of months were positive and 56% were negative. The best month was Feb 2024 with a return of +72.6%, while the worst month was Feb 2016 at -57.9%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 7 months.

On a daily basis, BNTC closed higher 44% of trading days. The best single day was Mar 23, 2021 with a return of +190.3%, while the worst single day was Feb 26, 2016 at -55.1%.

Benitec Biopharma Inc. has an annualized alpha of 10.80%, beta of 0.52, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since August 18, 2015.

• This stock participated in 173.77% of S&P 500 Index downside but only -36.52% of its upside - more exposed to losses than it benefited from rallies.
• Beta of 0.52 may look defensive, but with R2 of 0.01 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

BNTC ranks 31 for risk / return — below 31% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

Benitec Biopharma Inc. provided a 0.00% dividend yield over the last twelve months, with an annual payout of $0.00 per share.

The table displays the monthly dividend distributions for Benitec Biopharma Inc.. The dividends shown in the table have been adjusted to account for any splits that may have occurred.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Benitec Biopharma Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Benitec Biopharma Inc. was 99.92%, occurring on Aug 8, 2023. The portfolio has not yet recovered.

The current Benitec Biopharma Inc. drawdown is 99.46%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Benitec Biopharma Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Benitec Biopharma Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.